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1. Introduction 
Reverse epidemiology, or risk factor paradox, has been used to describe the observed effect 
that traditional risk factors for cardiovascular disease may not necessarily signify the same 
risk for hemodialysis patients (HP) as for healthy populations. In fact, recent published 
findings have suggested counter-intuitive outcomes (Chavalitdhamrong, Danovitch, & 
Bunnapradist, 2007; Tsirpanlis et al., 2009) regarding the role cholesterol may play in disease 
progression in HP with chronic inflammation and malnutrition comorbidities (Dungan, 
Guster, DeWalt, & Buse, 2007). However, contemporary experimental studies regarding 
reverse epidemiology are lacking. The few published findings on this topic suggest chronic 
inflammation, as measured by C-reactive protein (CRP), and malnutrition, as measured by 
albumin, is associated with normal cholesterol levels yet higher levels of mortality 
(Chavalitdhamrong, et al., 2007; Chmielewski, Carrero, Nordfors, Lindholm, & Stenvinkel, 
2008). 
In contrast, traditional risk factors such dyslipidemia, hyperhomocysteinemia, obesity, or 
hypertension may provide protective effects in HP, at least in the short term (Kalantar-
Zadeh, Block, Humphreys, & Kopple, 2003). Important predictors of clinical outcomes in HP 
are protein-energy wasting (malnutrition) (PEM) and inflammation (Fleischmann, Bower, & 
Salahudeen, 2001; Kalantar-Zadeh & Kopple, 2001; Kopple, 1997; Kopple, Zhu, Lew, & 
Lowrie, 1999; Lowrie & Lew, 1990; Nishizawa, Shoji, Ishimura, Inaba, & Morii, 2001). 
Because inflammation and PEM are interconnected and similarly affect markers of 
nutritional status both are considered part of a malnutrition inflammation complex (MIC) 
(Kalantar-Zadeh, et al., 2003; Kalantar-Zadeh & Kopple, 2001; Kalantar-Zadeh, Kopple, 
Block, & Humphreys, 2001). Thus, this chapter will address inflammation, malnutrition, 
cholesterol, and the overall concept of reverse epidemiology in HP relative to MIC as well as 
the implications of this information on short- and long-term treatment. 
2. Inflammation in hemodialysis patients 
2.1 Acute vs. chronic inflammation 
Initially, the inflammatory response is a defense mechanism to cellular injury or pathogenic 
invasion. The acute response includes vasodilatation, hyperemia and vascular permeability 
and can be detected within a relatively short amount of time (minutes to days) via an 
increase in neutrophils and the presence of fluid protein exudates (Sprague & Khalil, 2009). 
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Additional responders involved in the inflammatory response are cytokines (Sprague & 
Khalil, 2009) and acute phase proteins, which reach peak circulating levels within two days 
in the acute setting (Ceciliani, Giordano, & Spagnolo, 2002). Typically, the inflammatory 
process ceases when the mechanism responsible for cellular injury is removed, subsequent 
cellular intermediaries are inhibited, and healing takes place (Sprague & Khalil, 2009). 
However, in some instances that inflammatory process is not resolved. Thus, the response 
remains active and proceeds into a chronic process, which can result in necrosis and/or loss 
of functional tissue.  
2.2 Markers of inflammation in hemodialysis patients 
In HP the inflammatory response and markers of inflammation, namely CRP and the 
inflammatory cytokine interleukin-6 (IL-6), are predictive of mortality (Barreto et al., 2009; 
Pecoits-Filho, Barany, Lindholm, Heimburger, & Stenvinkel, 2002; Stenvinkel, Barany, 
Heimburger, Pecoits-Filho, & Lindholm, 2002; Yeun, Levine, Mantadilok, & Kaysen, 2000; 
Zimmermann, Herrlinger, Pruy, Metzger, & Wanner, 1999). In addition to CRP and IL-6, 
albumin and the inflammatory cytokine tumor necrosis factor-alpha (TNF-) are markers of 
inflammation commonly found in the literature. Each marker can provide evidence 
regarding the inflammatory state of HP, but there is debate as to which marker should be 
used and even debate as to the role in the inflammatory process of certain markers, namely 
CRP. For example, IL-6 and TNF- are known pro-inflammatory cytokines and are also 
associated with declining kidney function. Various cells including, macrophages and mast 
cells, produce TNF- and IL-6 (Sprague & Khalil, 2009). Among the numerous effects of 
TNF- are the stimulation of a febrile response, up-regulation of other cytokines, such as IL-
6, and stimulation of acute phase reactants (Sprague & Khalil, 2009). IL-6, in turn, has 
pleiotropic effects that include antibody secretion, the acute phase response and has also 
been shown to be pro-atherogenic, to name a few. However, TNF- and IL-6 are not 
typically used in clinical medicine and are more often found in research; therefore other 
means of assessing inflammation are used as these tests can become costly. Conversely, 
albumin and CRP are measurements of inflammation readily available to physicians. 
Interestingly, albumin levels are also commonly used to assess nutritional status as both 
nutrition and inflammation can affect albumin (more on this topic will be presented later in 
the chapter). 
CRP, however, is frequently used to confirm the presence of inflammation, as it is an acute 
phase protein produced by the liver and greatly regulated by IL-6. Additionally CRP is 
associated with reduction in nitric oxide production, induces monocyte recruitment and 
plays a strong role in foam cell formation. However, the causal role of CRP in cardiovascular 
events is still being debated (Genest, 2010; Lippi, Favaloro, Montagnana, & Franchini, 2010; 
Sattar & Lowe, 2006) and the use of CRP must be justified as it incurs added cost (Kaysen, 
2009). Regardless, it is a marker of inflammation that in the native form consists of five 
noncovalently bonded subunits and is termed pentameric CRP or pCRP. This is typically the 
CRP measured in plasma or serum, and is also known as high sensitivity CRP (hsCRP). 
High sensitivity CRP can dissociate into monomeric CRP (mCRP) after binding with 
activated platelets (Eisenhardt et al., 2009). New evidence suggests that mCRP, through the 
interaction of hsCRP with activated platelets, may play a more dominant role in the 
inflammatory process than hsCRP as mCRP was found to colocalize with macrophages and 
platelets (Eisenhardt, Habersberger, Murphy, et al., 2009).  High sensitivity CRP has also 
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been found in atherosclerotic lesions (Sun et al., 2005), but the antibodies used to detect CRP 
in this study detected both pCRP and mCRP (Eisenhardt, Habersberger, & Peter, 2009). It 
has been reported that once pCRP dissociates into mCRP, mCRP stimulates monocytes to a 
greater extent than pCRP, leads to increased monocyte adhesion, and exerts 
proinflammatory properties (Eisenhardt, Habersberger, Murphy, et al., 2009). Additionally, 
mCRP may be more effective at regulating LDL metabolism than pCRP (Ji, Wu, Potempa, 
Qiu, & Zhao, 2006). 
2.3 Causes of inflammation in hemodialysis patients 
Aside from the primary reason for the patient being placed on hemodialysis, often a disease 
associated with inflammation, dialysis and the integral pieces of hemodialysis can be 
sources of inflammation. Kaysen (2009) indicates that the type of vascular access used in 
dialysis, the insertion of the catheters, biofilm on catheters, bacterial components present in 
dialysate, and water supply can all be sources of inflammation (Kaysen, 2009). Markers of 
inflammation associated with vascular access alone include albumin (Chand, Teo, Fatica, & 
Brier, 2008; Wystrychowski et al., 2009), CRP (Costa et al., 2008; Movilli et al., 2006; 
Sachdeva, Kovalchuk, Bitzer, & Mokrzycki, 2009), and IL-6 (Costa, et al., 2008; Sachdeva, et 
al., 2009). As Kaysen (2009) points out, the type of vascular access in HP is associated with 
mortality (Xue, Dahl, Ebben, & Collins, 2003). Acutely, initial insertion of vascular access, 
especially catheter or arteriovenous graft (AVG), resulted in transient elevations of CRP and 
IL-6 whereas arteriovenous fistulas (AVF) did not demonstrate a transient rise in 
inflammatory markers (Sachdeva, et al., 2009). In regards to chronic inflammation, changing 
vascular access type from a catheter to AVG was shown to cause an increase in albumin, 
where as a change from AVG to catheter caused a decrease in albumin (Wystrychowski, et 
al., 2009). Similarly, catheter and AVG use have been demonstrated to result in elevated 
levels of CRP and IL-6 and lower levels of albumin than AVF (Costa, et al., 2008; Movilli, et 
al., 2006). Thus, the type of vascular access has an impact on inflammation levels. An 
additional impact on inflammation levels is adipose tissue as adipocytes produce IL-6 
(Fasshauer, Klein, Lossner, & Paschke, 2003), which is also a strong predictor of mortality in 
HP (Barreto, et al., 2009; Pecoits-Filho, et al., 2002; Stenvinkel, et al., 2002). 
3. Malnutrition in hemodialysis patients  
3.1 Albumin as a marker of nutritional status 
Albumin is the most abundant plasma protein with a half-life of about twenty-one days. It is 
a negative acute-phase protein that functions to maintain oncotic pressure and act as a 
transport protein (Carlson, 2004). Normal serum albumin concentration is between 3.5 and 
5.2 g/dL, and this reference range is often utilized as a marker of nutritional status in 
healthy older populations (Carlson, 2004; Covinsky, Covinsky, Palmer, & Sehgal, 2002). The 
cutoff point for low serum albumin concentration (hypoalbuminemia) has been proposed to 
be even higher at about 3.9 g/dL in HP (Trivedi, Xiang, & Klein, 2009). However, it must be 
noted that conclusions derived from measures of serum albumin concentration are not 
always in agreement with the conclusions derived from clinical assessments regarding 
nutritional status (Covinsky, et al., 2002). Forty HP with CRP levels below 0.80 mg/dL were 
evaluated for malnutrition by measuring serum albumin and through the use of the 
Subjective Global Assessment (SGA) described by Detsky, McLaughlin, and Baker et al. 
(1987). The SGA was used to determine whether a patient was classified as well-nourished 
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or malnourished. Using 3.5 g/dL as the cutoff point for hypoalbuminemia resulted in a 
sensitivity of just 14.3% compared to the results of the SGA. Raising the hypoalbuminemia 
cutoff point to 4.1 g/dL increased the sensitivity of the measurement to 64%. Furthermore, 
the mean albumin concentrations for the well-nourished and malnourished groups were 4.3 
g/dL and 4.0 g/dL, respectively, with considerable overlap between the two groups. These 
data suggest that serum albumin alone may not be a sensitive marker of malnutrition in the 
absence of inflammation in HP (Santos et al., 2003). Regardless, serum albumin is a very 
important marker of mortality risk in HP (Iseki, Kawazoe, & Fukiyama, 1993). Despite the 
lack of total agreement with clinical assessments of nutritional status, hypoalbuminemia has 
been demonstrated to be an independent risk factor for all-cause mortality in older persons 
especially when combined with measures of physical disability (Corti, Guralnik, Salive, & 
Sorkin, 1994). Additionally, hypoalbuminemia is associated with mortality in various 
disease populations including cardiovascular, cancer, and HP (Iseki, et al., 1993; Phillips, 
Shaper, & Whincup, 1989). A 1 g/dL reduction in serum albumin has been associated with a 
47% greater risk of mortality in HP, with the serum albumin concentration in these 
particular HP being linked to inflammation more so than the presence of malnutrition (de 
Mutsert et al., 2009).  
3.2 Regulation of serum albumin: malnutrition and inflammation  
Serum albumin concentration is controlled by the rate of its synthesis, fractional catabolic 
rate (FCR), and distribution between intra and extravascular compartments. These three 
variables controlling albumin concentration are heavily influenced by both nutritional status 
and inflammation (Kaysen, 2003). In healthy individuals and HP without inflammation that 
are malnourished, albumin levels usually stay within a normal range until the degree of 
starvation is preterminal (Kaysen, 2009). Renal disease is associated with anorexia and PEM 
due to the build-up of uremic toxins. Additionally, hemodialysis for the removal of these 
toxins is also associated with anorexia and PEM because of the resulting nausea and post-
dialysis fatigue (Bergstrom, 1996). PEM leads to a decreased rate of albumin synthesis. In 
normal individuals, the FCR of albumin and resting energy expenditure are also down-
regulated in order to compensate for its decreased synthesis during periods of PEM. For HP 
that are in an inflammatory state, normal down-regulation of FCR is blunted leading to an 
imbalance between albumin synthesis and catabolism that result in hypoalbuminemia 
(Kaysen, 2009). Even in the absence of malnutrition, positive acute phase proteins that result 
from the production of pro-inflammatory cytokines are associated with decreased albumin 
synthesis. Additionally, inflammation leads to a greater than normal albumin FCR for a 
given serum albumin level (Kaysen, 2003). On top of the challenges presented by 
malnutrition and inflammation in HP, amino acid loss from hemodialysis itself may 
contribute further to nitrogen restriction and hypoalbuminemia (Kaysen, 2009).  
3.3 Nutritional supplementation and hemodialysis patients  
Recently, studies have investigated the effects of protein and amino acid supplements on 
serum albumin levels in HP (Bolasco, Caria, Cupisti, Secci, & Saverio Dioguardi, 2011; 
Moretti, Johnson, & Keeling-Hathaway, 2009; Taylor et al., 2011). When selecting an 
appropriate nutritional supplement for HP, phosphorus levels must be taken into 
consideration as it has been demonstrated that high-protein intake with concurrent low-
phosphorus ingestion and normal serum phosphorus levels is associated with the lowest 
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mortality rate among HP (Kalantar-Zadeh et al., 2010). Supplementation with 15 grams of 
liquid hydrolyzed collagen protein three times per week after each hemodialysis treatment 
in one crossover group increased serum albumin by month 3 of supplementation. However, 
this change was small (+0.03 g/dL) and was not sustained throughout the remaining 3 
months of treatment (Moretti, et al., 2009). Conversely, two pilot studies have shown 
promising effects of nutritional supplementation on serum albumin. In one study, 
maintenance HP consumed eight ounces of egg whites (egg whites are low in phosphorus) 
once per day for six weeks (Taylor, et al., 2011). Mean serum albumin concentrations 
increased by 0.19 g/dL along with a fall in mean serum phosphorus of 0.94 mg/dL. In the 
other pilot study, four grams of oral amino acid supplementation three times daily increased 
mean serum albumin concentration by 0.50 g/dL after 3 months of treatment (Covinsky, et 
al., 2002). Also, inflammation was attenuated in the study group as demonstrated by a 
decrease in CRP levels. Based on these pilot studies, protein and amino acid 
supplementation may benefit HP, but more research including larger sample sizes with 
controlled trials is needed before a definite conclusion or treatment protocol can be 
formulated.  
4. Cardiovascular disease and hemodialysis patients  
The number of HP patients in the United States is approximately 350,000 with an 
expectation of reaching 1.5 million by 2016. Most HP have a significant decline in quality of 
life with two-thirds dying within 5 years of dialysis initiation; a survival rate worse than 
most cancers (Kilpatrick et al., 2007). Cardiovascular disease (CVD) is a leading cause of 
death in HP with rates higher than the general population and risk primarily associated 
with elevated lipids, inflammation, malnutrition, hypertension, hyperhomocysteinemia, 
obesity, and insulin resistance (Third Report of the National Cholesterol Education Program 
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults 
(Adult Treatment Panel III) Final Report, 2002). Most HP patients’ elevated lipid profiles are 
associated with a higher incidence of CVD morbidity and mortality (Vaziri, 2009) and all-
cause mortality (Tsirpanlis, et al., 2009). Additionally, non-fatal CVD is 10-30 times higher in 
HP suggesting this population is more prone to heart disease (Nanayakkara & Gaillard, 
2010). Though traditional treatment of CVD in HP has demonstrated promise, many large 
randomized trials in HP have not demonstrated a survival benefit from traditional treatment 
strategies (Nanayakkara & Gaillard, 2010). The challenge becomes understanding why 
traditional risk factors are less predictive and whether the progression of disease is so 
advanced in HP that risk factor management should be different in this patient population. It 
should be noted however, that traditional and non-traditional risk factors for CVD in HP do 
have some crossover, complicating our understanding of how risk factor management may 
assist in disease causation and association. Though this chapter focuses on HP, chronic kidney 
disease patients who are predialysis share some of the same counter-intuitive findings. 
Therefore it should be noted that progression of CVD begins well before HP begin dialysis and 
could be detected as early as stage I CKD. Finally, it has been suggested that plaque 
accumulation may occur differently in HP. In the general population arterial plaque is more 
associated with lipid accumulation, but with HP it is more likely to be associated with calcified 
plaques and increased arterial stenosis (Diepeveen, Wetzels, Bilo, van Tits, & Stalenhoef, 2008).  
Various research groups, including the National Cholesterol Education Program (NCEP) 
(Third Report of the National Cholesterol Education Program Expert Panel on Detection, 
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Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) 
Final Report, 2002) have established that lipids play a significant role in the progression of 
CVD and with reductions in cholesterol levels there is a similar and graded reduction in risk 
(Kalantar-Zadeh, et al., 2003). Dyslipidemia characterized in HP is primarily associated with 
hypertriglyceridemia, low HDL concentrations, elevated levels of LDL, elevated LDL 
particle numbers, a higher propensity of smaller and denser LDL particles which contain 
high levels of residual triglycerides, and elevated levels of lipoprotein (a) (Vaziri, 2009). 
Cholesterol metabolism in HP can be significantly altered by dialysis protocol, lipid 
controlling medication, malnutrition, and inflammation (Montazerifar, Hashemi, Karajibani, 
& Dikshit, 2010). HDL can be significantly reduced in HP due to a reduced plasma 
concentration of ApoA-I and ApoA-II (Bowden, Hebert, Wilson, Gentile, & Lanning, 2007; 
Vaziri, 2009), reduced transporter proteins such as ABCA-1 (Vaziri, 2009), and the down-
regulation of enzymatic process associated with HDL maturation (Malgorzewicz et al., 
2010). Down-regulation also occurs with HDL paraoxonase which is associated with 
impaired protection against oxidative stress. Hypertriglyceridemia also occurs in HP, is 
normally associated with impaired VLDL and is the most prominent dyslipidemic 
abmormality reported in 70% of HP (Eisenhardt, Habersberger, & Peter, 2009). Additionally, 
hypertriglyceridemia is associated with increases in IDL, chylomicrons, and chylomicron 
remnants postprandial (Chmielewski, et al., 2008). Primarily a reduction in lipoprotein 
lipase, an enzyme associated with binding to VLDL and the release of the corresponding 
triglycerides, is associated with changes that cause a concomitant increase in plasma 
triglycerides that seems to correspond with a decrease in VLDL receptors. Finally, LDL in 
HP is normally more atherogenic as particles are usually smaller, denser and are more likely 
to be oxidized and engulfed by macrophages leading to more unstable arterial plaques 
(Kaysen, 2009). Oxidation can further cause LDL to no longer be recognizable to LDL 
receptors on the cell causing less deposition of LDL in intracellular pools. Less deposition 
can lead to the same amount of circulating LDL cholesterol being associated with smaller 
and denser LDL particles which can carry more risk for CVD. Excess LDL cholesterol is then 
removed from circulation primarily by being engulfed by macrophages which lead to more 
atherogenic foam cells leading to risk acceleration. Lipoprotein (a) is a LDL-like lipid with 
higher levels associated with increased risk of CVD and is associated with overproduction 
of apolipoproteins, specifically apoB. Apolipoprotein B is bound with LDL and is associated 
with increased numbers of LDL particles.    
4.1 Reverse epidemiology 
Though cholesterol metabolism in HP is associated with dyslipidemia and many CVD 
related deaths are associated with elevated levels of lipoproteins, recent evidence suggests 
that many HP have normal or reduced plasma cholesterol levels that are associated with a 
higher rate of mortality (Bowden & Wilson, 2010). CVD related mortality accounts for 40-
45% of all-cause mortality in HP suggesting factors other than lipids may be associated with 
CVD in this patient population (Dungan, et al., 2007; Tsirpanlis, et al., 2009). Counter-
intuitive outcomes regarding the role cholesterol may play in disease progression in HP 
may be affected by chronic inflammation and malnutrition with much of the published 
literature concerned with MIC (Bowden & Wilson, 2010; Chavalitdhamrong, et al., 2007). 
The term, though controversial, that has been used in the literature associated with this 
counter-intuitive finding is reverse epidemiology (Dungan, et al., 2007). Experimental 
www.intechopen.com
 
Malnutrition, Inflammation and Reverse Epidemiology in Hemodialysis Patients 
 
303 
studies are deficient, but the few published on this topic have suggested that HP with 
chronically elevated levels of inflammation, as measured by C-reactive protein (CRP) or 
interleukin-6 (IL-6), and malnutrition, as measured by albumin, are associated with normal 
cholesterol values but higher levels of mortality (Chavalitdhamrong, et al., 2007; 
Chmielewski, et al., 2008).  
5. Malnutrition-inflammation complex 
Cano et al. (2009) has reported that between 20-60% of HP may have MIC and that patients 
also have lower body weights, lower BMI, lower albumin levels, lower blood pressure and 
elevated CRP (Diepeveen, et al., 2008). Albumin has been specifically mentioned as a marker 
of nutritional status and identified as one of the criteria used to measure PEM which is 
associated with MIC. The association between hypoalbuminemia (< 3.9 mg/dL) and 
mortality has been well-established and albumin has been identified as a strong predictor of 
cardiovascular disease (Kaysen, 2009). Supporting this theory is the fact that most studies 
reporting on reverse epidemiology report no counter-intuitive findings with HDL. The 
cholesterol esters in HDL are primarily received from albumin (Vaziri, 2009) and therefore 
hypoalbuminemia would be associated with low HDL. This is also one possible explanation 
for why other lipoproteins would be low, yet still associated with a significantly higher 
mortality rate in HP. Challenging our understanding of how this might impact mortality 
and cholesterol is that albumin is also used as a measure of inflammation and may not 
necessarily be related a nutritional etiology (Trivedi, et al., 2009). Finally, CRP along with IL-
6 are inflammatory markers that have been associated with higher rates of mortality as well 
(Bowden & Wilson, 2010). 
5.1 Reverse epidemiology and cholesterol 
In a subset of HP a decrease in baseline cholesterol levels, excluding HDL, has been 
associated with decreases in CVD mortality and all-cause mortality when patients have 
chronic levels of inflammation and poor nutritional status (Krane et al., 2009). Recent study 
authors have suggested the need to consider both malnutrition and inflammation 
simultaneously as albumin has been shown to be affected by inflammation levels. 
Inflammatory cytokines and acute phase reactants have been reported to decrease appetite, 
reduced albumin, increase catabolism (Liu et al., 2004) and quite possibly cause lower levels 
of cholesterol suggesting that low albumin levels may simply be a reflection of inflammation 
rather than malnutrition. Specifically most lipoproteins seem to be affected by MIC with the 
exception of HDL. In most studies where HDL was either low or unaffected most patients 
experience hypoalbuminemia and low protein intake in the diet (Kilpatrick, et al., 2007). 
Krane et al. (2009) in a study of 1,229 Type II diabetics who were HP reported that high 
levels of CRP strongly predicted all-cause mortality, sudden death and myocardial 
infarction when cholesterol levels were both low and high. Yet, when CRP levels were high 
and cholesterol levels were low, relative risks for CVD related deaths were even greater. It 
was further reported that CRP level and not LDL level was the variable more likely to 
predict risk for mortality and cardiovascular events. Another study confirmed the existence 
of reverse epidemiology in the presence of high inflammation suggesting the inflammation 
better predicted both morbidity and mortality (Tsirpanlis, et al., 2009). The study authors 
also reported that nutritional cachexia along with low cholesterol were good nutritional 
indices for malnutrition and may be the reason low cholesterol levels are associated with 
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higher levels of mortality in HP. A more recent study reported on the cross-sectional 
association with MIC and the effects on cholesterol in HP (Bowden & Wilson, 2010). When 
comparing cholesterol levels, those classified as having hypoalbuminemia had a reverse 
epidemiological effect with LDL particle number. In the same study when HP were 
classified as having high inflammation, based on CRP, LDL, VLDL, and LDL particle 
number reported counter-intuitive findings. But, in patients classified as having both 
hypoalbuminemia and high inflammation, all lipid variables, with the exception of HDL, 
reported a reverse epidemiological effect. This suggests that though inflammation may play 
a more prominent role with reverse epidemiology, both inflammation and malnutrition can 
have a pronounced effect on lipids causing low cholesterol levels to be associated with more 
mortality. Additionally, other study authors have reported inverse associations with 
cholesterol and all-cause mortality, but also a U-shaped relationship with cholesterol in the 
presence of malnutrition and inflammation (Liu, et al., 2004). When malnutrition and 
inflammation were controlled for in the analysis, a strong, graded and positive association 
existed between high cholesterol levels and mortality further supporting the thought that 
reverse epidemiological associations with cholesterol in HP is associated with MIC. An 
additional review paper has suggested that previous studies that have controlled 
statistically for factors associated with MIC in HP, risk associated with cholesterol was the 
same as the general population and further speculates that cholesterol may be an additional 
marker of malnutrition (Chmielewski, et al., 2008). It should be noted that not all studies 
agree with these findings. 
Another theory behind why low cholesterol in HP patients can be associated with high 
mortality has been called survival selection. It is well-established that most chronic kidney 
disease patients will not survive to kidney failure and End-Stage Renal Disease. Presently, it 
is suggested that only 10% (Trivedi, et al., 2009) of patients will live long enough to initiate 
dialysis. Therefore, since so few survive it is thought that only those who have a strong 
genetic predisposition for survival may be more likely to live but may also have a poorer 
risk profile. Additionally, simply stated, HP may not live long enough to die of the 
consequences of traditional CVD risk factors. Though this theory is not very new, it has yet 
to be confirmed with well controlled studies that take into consideration the age of the 
patients. Kalantar-Zadeh et al. (2003) also suggests that reverse epidemiology may be 
normal and that over-nutrition is primarily a 20th and 21st century phenomenon and that our 
understanding of traditional Framingham risk factors may in fact be new and the exception. 
Though over-nutrition is a problem in many countries it has been associated with longer 
living populations in Western nations. As one would expect this idea is highly controversial 
among scientist and nephrologists.    
Additional study authors (Nanayakkara & Gaillard, 2010) have reported reverse 
epidemiology in HP concerning lipids could possibly be due oxidative stress. Reactive 
oxygen species (ROS) production that is not balanced by antioxidant control is associated 
with oxidative stress. Furthermore, oxidative injury has been reported to alter lipids in both 
the general population and HP and is involved in CVD acceleration (Diepeveen, et al., 2008). 
Though HP are normally supplemented with B vitamins and folic acid, many still have 
deficiencies in antioxidants with many patients shifting to a more pro-oxidative stress 
profile. High oxidized LDL is a well established comorbidity in both HP and CKD patients 
and is associated with small, dense LDL particles. Moreover, modification of LDL through 
oxidation is thought to be the first step in the development of CVD and specifically 
atherosclerosis. Oxidative stress occurs routinely in HP, especially in patients with a long-
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term dialysis vintage, making LDL smaller and denser and is associated with more 
endothelial dysfunction, inflammation, stenosis and intima media thickness. Therefore, the 
oxidative stress hypothesis may help to further explain reverse epidemiology. Oxidative 
stress in combination with MIC could cause lower levels of LDL and LDL particle numbers, 
but more atherogenic particles that can accelerate mortality and morbidity.  Yet, those 
associations do exist, a causal relationship between oxidative stress, CVD, and reverse 
epidemiology has yet to be established suggesting the need for further study. 
Chmielewski (2008) reports on an endotoxinlipoprotein hypothesis that suggests higher 
levels of cholesterol may be beneficial in HP. The theory suggests that higher levels of 
lipoproteins more readily bind bacterial lipopolysaccharide or endotoxins and modulate 
inflammatory immune responses. The authors continues to state that cholesterol levels and 
their ability to predict CVD fall on a continuum with lower and higher levels associated 
with mortality (Kalantar-Zadeh, 2007). Liu, et al. (2004) may help support this theory as they 
have reported a U-shaped curve regarding cholesterol levels and moratlity in HP. This 
theory is highly speculative and needs further study. 
Finally, as mentioned previously, HP patients have been reported to have smaller, dense 
LDL particles that are more oxidized which may play a stronger role than LDL. Small LDL 
particle size has been identified as an emerging risk factor for CVD (Third Report of the 
National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of 
High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report, 2002). A previous 
study (Bowden, Griggs, Wilson, & Gentile, 2009) has demonstrated that LDL particle 
number and LDL size can classify more HP at risk when compared to LDL and triglycerides. 
Since more HP have small, dense LDL particles there may be mortality associated with 
smaller LDL particles even when LDL particle number is lower. Therefore, though HP may 
have less LDL cholesterol and less of the smaller LDL particles, because smaller LDL 
particles are more atherogenic, more patients have increased morality with decrease levels 
of cholesterol.  
6. Treatment 
Reverse epidemiology has been associated with cholesterol but also body mass index (BMI), 
systolic and diastolic blood pressure, homocysteine, and creatinine levels (Balakrishnan & 
Rao, 2007) in HP suggesting the need for novel treatments. Since the counter-intuitive 
findings are prevalent in HP additional approaches are necessary to help identify novel 
treatments and to discover if new therapies are warranted. Though counter-intuitive 
findings are present in HP as well as advanced age, congestive heart failure, malignancies, 
and AIDS little data exists to support changes in non-traditional risk factors as a means to 
control CVD. To help increase albumin levels it has been proposed to increase protein 
content in the diet. But levels of protein augmentation with HP patients on chronic 
hemodialysis has not been sufficiently elucidated simply because dietary protein can be a 
significant source of uremic toxins and increase phosphate levels which can have deleterious 
effects on the health of HP patients (Stolic, 2010). It should be noted that hypercaloric 
consumption may take several years and even decades for serious health effects to occur, yet 
hypocaloric consumption, measured by albumin levels in HP patients, normally causes a 
more rapid deterioration in health. Combined with high inflammation levels, a decreased 
appetite and hypocaloric levels may cause a significant decrease in cholesterol but 
accelerated risk for mortality (Kalantar-Zadeh, et al., 2001). This short-term effect of 
www.intechopen.com
 
Progress in Hemodialysis – From Emergent Biotechnology to Clinical Practice 
 
306 
malnutrition enhanced by inflammation may overcome the long-term impact of traditional 
risk factors for CVD and may cause the HP patients to not live long enough to develop 
elevated levels of cholesterol causing them die sooner than is expected. Also, evidence 
suggests that lipid levels become more elevated and more strongly associated with CVD the 
longer the HP receives dialysis and suggests that even though counter-intuitive cholesterol 
findings are evident in early dialysis traditional therapies such as statins, fibrates and niacin 
are necessary even with cholesterol levels are low (Chavalitdhamrong, et al., 2007). 
Therefore, treatment for HP patients with MIC needs to focus short-term on inflammation 
and malnutrition through dietary counseling and medication. Once MIC is controlled, a 
more long-term therapy may need to look at controlling lipids associated with CVD risk.  
7. Conclusions  
Reverse epidemiology in cholesterol levels associated with HP introduces a number of 
questions concerning our understanding of CVD and findings from the Framingham study. 
The questions becomes whether nephrologists should recommend the same cut-points for HP 
as is normally used in general populations. Should nephrologists attempt to control 
malnutrition and inflammation first and focus on lipids once HP have MIC under control?  
Though statins can help control lipids they may also help control inflammation which in turn 
may help to regulate appetite and increase albumin levels suggestions that statin therapy may 
still need to be used in most HP. Finally, more clinical trials are needed to discover if reverse 
epidemiology is “normal” in HP or simply a new understanding of traditional risk factors.    
 
Author Year Sample Population 
Study 
Design
Study Findings 
Bowden, 
et al 
In 
Press 
438 HP Prospective 
~ 3 years 
Reverse epidemiological 
effects for total cholesterol, 
LDL, LDL particle number, 
LDL, triglycerides, and 
VLDL 
Bowden, 
et al 
2010 105 HP Cross-
sectional 
Reverse epidemiology in 
number in 
hypoalbuminemia group; 
LDL, VLDL, and LDL 
particle number in inflamed 
group; total cholesterol, 
VLDL, large VLDL, 
triglycerides, Lp(a), LDL, 
and LDL particle number in 
hypoalbuminemia and 
inflamed group 
Bowden, 
et al 
2009 117 HP Cross-
sectional 
Reverse epidemiology effect 
existed for LDL, large LDL, 
LDL particle size, and HDL 
Krane,    
et al 
2009 1255 HP with 
Type II 
Diabetes 
Prospective 
~ 4 years 
Patients with low 
cholesterol and high 
inflammation had an 
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adjusted relative risk 
equivalent to patients with 
high cholesterol and low 
inflammation in CVD death 
and all-cause mortality 
Tsirpanlis, 
et al 
2009 136 HP Prospective 
~ 2 years 
Low cholesterol levels 
together with selected 
inflammatory markers 
predict CVD and all-cause 
mortality and morbidity 
Kilpatrick, 
et al 
2007 15,859 HP Prospective 
~ 3 years 
Inverse associations 
between hyperlipidemia 
and survival, however, 
black HP with high LDL 
show almost two-fold 
increase in cardiovascular 
death risk 
Liu, et al 2004 823 HP Prospective 
~ 3 years 
Inverse association of 
cholesterol levels with all-
cause mortality and a U-
shaped relationship with 
CVD mortality in the 
presence of 
inflammation/malnutrition 
Iseki, et al 2002 1167 HP Prospective 
~ 10 years 
Hypercholesterolemia was 
an independent predictor 
on survival but was only 
evident in a sub-group of 
patients whose serum 
albumin was more than 4.5 
g/dl 
Table 1. Studies reporting a reverse epidemiology affect regarding cholesterol and HP (2002-
Present). 
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